

CITATION REPORT

List of articles citing

Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial

DOI: 10.1001/jamaophthalmol.2014.2772
JAMA Ophthalmology, 2014, 132, 1327-33.

Source: <https://exaly.com/paper-pdf/58583931/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
242	Retinopathy of prematurity: New developments bring concern and hope. 2015 , 51, 765-70		19
241	Laser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity. 2015 , 55, 81-90		3
240	Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity. 2015 , 78, 300-4		27
239	Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy. 2015 , 234, 211-7		24
238	Author reply: To PMID 25001158. <i>Ophthalmology</i> , 2015 , 122, e48	7.3	
237	A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. 2015 , 10, e0129383		51
236	Re: Lepore et al.: Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings (<i>Ophthalmology</i> 2014;121:2212-9). <i>Ophthalmology</i> , 2015 , 122, e47-8	7.3	
235	Oral Propranolol: A New Treatment for Infants with Retinopathy of Prematurity?. 2015 , 108, 49-52		12
234	Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. 2015 , 19, 140-4		35
233	Retinopathy of prematurity: recent developments in diagnosis and treatment. 2015 , 10, 167-182		5
232	Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. 2015 , 15, 20		44
231	Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. <i>Ophthalmology</i> , 2015 , 122, 1008-15	7.3	129
230	Review of the latest treatments for retinopathy of prematurity: laser photo-ablation versus intravitreal anti-VEGF agents in the management of high-risk pre-threshold (type 1) disease. 2015 , 10, 421-430		1
229	Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy. 2016 , 8, 81-90		15
228	Review of effects of anti-VEGF treatment on refractive error. 2016 , 8, 135-140		17
227	Current Practice Patterns for Treatment of Retinopathy of Prematurity. 2016 , 47, 491-5		8
226	Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy. 2016 , 46, 764-8		

225	Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. 2017 , 101, 365-370		30
224	Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity. 2016 , 24, 84-8		15
223	Manual of Retinal Diseases. 2016 ,		1
222	Retinopathy of Prematurity. 2016 , 51-55		
221	Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. 2016 , 6, 27082		25
220	Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review. 2016 , 20, 539-540.e3		7
219	Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes. 2016 , 20, 478-480		5
218	Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy. <i>Ophthalmology</i> , 2016 , 123, 1845-55	7.3	98
217	Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. 2016 , 2, CD009734		32
216	Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. 2016 , 137,		165
215	Concerns for Development After Bevacizumab Treatment of ROP. 2016 , 137,		25
214	Visual outcome and refractive status in first 3 years of age in preterm infants suffered from laser-treated Type 1 retinopathy of prematurity (ROP): a 6-year retrospective review in a tertiary centre in Hong Kong. <i>International Ophthalmology</i> , 2018 , 38, 163-169	2.2	4
213	Assessment of Lower Doses of Intravitreal Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. <i>JAMA Ophthalmology</i> , 2017 , 135, 654-656	3.9	77
212	Axial Length and Anterior Segment Alterations in Former Preterm Infants and Full-Term Neonates Analyzed With Scheimpflug Imaging. 2017 , 36, 821-827		20
211	Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. <i>Ophthalmology</i> , 2017 , 124, 619-633 ^{7.3}	7.3	76
210	Anti-Vascular Endothelial Growth Factor Medications in Retinopathy of Prematurity. 2017 , 2, 75-86		
209	OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURETY IN ZONE I. 2017 , 37, 88-96		40
208	The neural retina in retinopathy of prematurity. 2017 , 56, 32-57		49

207	Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. 2017 , 42, 462-469		39
206	Anti-VEGF for ROP and Pediatric Retinal Diseases. 2018 , 7, 145-151		11
205	Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity. 2018 , 7, 136-144		6
204	Hot Topics in Retinopathy of Prematurity. 2017 , 46, e415-e422		7
203	Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies. 2017 , 14, 165		70
202	Pathophysiology of Retinopathy of Prematurity. 2017 , 1681-1686.e2		
201	Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity. 2018 , 2, 942-948		17
200	[Long-term effects of anti-VEGF therapy for retinopathy of prematurity]. <i>Ophthalmologe</i> , 2018 , 115, 464-468	1.6	2
199	[Treated cases of retinopathy of prematurity in Germany : 5-year data from the Retina.net ROP registry]. <i>Ophthalmologe</i> , 2018 , 115, 476-488	1.6	5
198	Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. 2018 , 1, CD009734		51
197	Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. 2018 , 22, 61-65.e1		52
196	PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATUREITY. 2018 , 38, 764-772		52
195	SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATUREITY. 2018 , 38, 1595-1604		20
194	Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective. 2018 , 62, 77-119		60
193	Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings. <i>Ophthalmology</i> , 2018 , 125, 218-226	7.3	59
192	Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity. <i>Ophthalmology</i> , 2018 , 125, 444-452	7.3	24
191	Rescue with intravitreal bevacizumab in aggressive posterior retinopathy of prematurity poorly responsive to laser treatment. 2018 , 3, 9-9		
190	Screening Examination of Premature Infants for Retinopathy of Prematurity. 2018 , 142,		163

189	Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. 2018 , 32, 451-458		10
188	[Ultra-Wide Field Retinal Imaging and Angiography in the Differential Diagnosis and Therapeutic Decisions in Vascular Diseases of the Peripheral Retina]. 2018 , 235, 980-993		0
187	Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226). <i>Ophthalmology</i> , 2018 , 125, e70-e71	7.3	3
186	How Does the Standard of Care Evolve? Anti-Vascular Endothelial Growth Factor Agents in Retinopathy of Prematurity Treatment as an Example. <i>Ophthalmology</i> , 2018 , 125, 1485-1487	7.3	2
185	Functional and Structural Outcomes of Temporal Zone II-Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab in Retinopathy of Prematurity. 2018 , 2018, 2376240		3
184	[Review of clinical trials in retinopathy of prematurity : Current state and future perspectives]. <i>Ophthalmology</i> , 2018 , 115, 456-463	1.6	2
183	Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment. 2018 , 192, 20-30		21
182	Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes. 2018 , 32, 1752-1759		7
181	Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial. 2018 , 8, e021749		5
180	Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). 2018 , 18, 19		22
179	Eye and Vision Disorders. 2018 , 1536-1557.e4		1
178	A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. <i>Ophthalmology</i> , 2018 , 125, 1961-1966	7.3	49
177	Increased incidence of retinopathy of prematurity and evolving treatment modalities at a Canadian tertiary centre. 2019 , 54, 269-274		4
176	Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. 2019 , 103, 494-498		15
175	Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment. 2019 , 144,		41
174	Effect of Eye Masks on Neonatal Stress Following Dilated Retinal Examination: The MASK-ROP Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2019 , 137, 1265-1272	3.9	5
173	Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity. 2019 , 11, 25-35		6
172	Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP. 2019 , 23, 88.e1-88.e6		7

171	Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity. 2019 , 33, 272-278		5
170	Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: A Prospective Case-Control Study. <i>Ophthalmology</i> , 2019 , 126, 1567-1577	7.3	28
169	Pediatric Retinal Vascular Diseases. 2019 ,		
168	Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity. 2019 , 43, 375-380		16
167	Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP. <i>International Ophthalmology</i> , 2019 , 39, 2697-2705 ²		6
166	VEGF in Signaling and Disease: Beyond Discovery and Development. 2019 , 176, 1248-1264		617
165	Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity. 2019 , 63, 262-268		3
164	A review of treatment for retinopathy of prematurity. 2019 , 14, 73-87		13
163	The use of bevacizumab in pediatric retinal and choroidal disease: A review. 2019 , 29, 338-347		6
162	Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity. 2019 , 2019, 3935945		3
161	Prediction of visual outcomes by an artificial neural network following intravitreal injection and laser therapy for retinopathy of prematurity. 2020 , 104, 1277-1282		1
160	Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review. 2019 , 14, e0225643		15
159	Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy. 2018 , 7, 56-62		13
158	Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity. 2019 , 31, 61-65		4
157	Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression. <i>International Ophthalmology</i> , 2019 , 39, 2267-2274	2.2	11
156	Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety. 2019 , 22, 369-382		13
155	Innovative Approaches in the Delivery of Primary and Secondary Eye Care. 2019 ,		1
154	Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety. 2019 , 103, 1332-1336		12

153	[Pediatric Retinal Detachment]. 2019 , 236, 74-87		3
152	TEN-YEAR EPIDEMIOLOGY OF RETINOPATHY OF PREMATUREITY TREATMENT IN TAIWAN. 2020 , 40, 1804-1811		3
151	Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity. 2020 , 103, 495-500		
150	Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP). 2020 , 28, 49-54		2
149	Retinal laser services in Bhutan: a 3-year national survey. 2020 , 20, 404		0
148	[Statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020]. <i>Ophthalmologe</i> , 2020 , 117, 873-885	1.6	3
147	Predictors and ocular outcomes of rescue treatment in preterm infants with treated retinopathy of prematurity-a retrospective study. 2021 , 35, 1937-1945		
146	ANATOMICAL AND FUNCTIONAL RESULTS OF INTRAVITREAL AFLIBERCEPT MONOTHERAPY FOR TYPE 1 RETINOPATHY OF PREMATUREITY: One-Year Outcomes. 2020 , 40, 2366-2372		4
145	Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity. 2021 , 35, 2820-2825		1
144	Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases. 2020 , 21,		3
143	Microcornea and Thickened Lens in Angle Closure following Nonsurgical Treatment of Retinopathy of Prematurity. 2020 , 2020, 7510903		3
142	Update in the Treatment of Retinopathy of Prematurity. 2020 ,		3
141	Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. 2020 , 104, 691-696		5
140	Hypertension and Neuroimaging Changes After Bevacizumab for Retinopathy of Prematurity. 2020 , 145,		6
139	Myopia and anterior segment optical coherence tomography findings in laser-treated retinopathy of prematurity eyes. 2020 , 24, 86.e1-86.e7		6
138	Influence of polymorphisms in , , and genes on retinopathy of prematurity risk: a Meta-analysis. 2020 , 1-10		1
137	Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2020 , 258, 1205-1210	3.8	3
136	Strategies to Prevent Severe Retinopathy of Prematurity: A 2020 Update and Meta-analysis. 2020 , 21, e249-e263		18

135	Foveal thickness, foveal microvasculature, and refractive error in children with asymmetric involvement of retinopathy of prematurity. 2021 , 31, 759-765		0
134	Myopia in school-aged children with preterm birth: the roles of time spent outdoors and serum vitamin D. 2021 , 105, 468-472		4
133	Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020. <i>Ophthalmologe</i> , 2021 , 118, 68-77	1.6	0
132	Intravitreal anti-vascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes. 2021 , 66, 572-584		6
131	Does the number of laser applications for ROP treatment influence the degree of myopia?. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2021 , 259, 317-322	3.8	0
130	Augenärztliche Screening-Untersuchung bei Frühgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr. 024/010, März 2020). 2021 , 225, 19-33		1
129	Evaluation of the Effect of Different Treatment Management on Refractive Outcomes in Severe Retinopathy of Prematurity.. 2021 , 55, 545-550		0
128	Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors. 2021 , 7, 5		8
127	Effects of diode laser photocoagulation treatment on ocular biometric parameters in premature infants with retinopathy of prematurity. 2021 , 14, 277-282		1
126	Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. 2021 ,		2
125	Management of retinopathy of prematurity (ROP) in a Polish cohort of infants. 2021 , 11, 4522		2
124	Refractive outcomes after intravitreal injection of anti-vascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis. 2021 , 11, e042384		0
123	Bevacizumab and neurodevelopmental outcomes of preterm infants with retinopathy of prematurity: should we still worry?. 2021 , 1-8		0
122	[Guidelines for ophthalmological screening of premature infants in Germany (S2k level, AWMF guidelines register no. 024/010, March 2020) : Joint recommendation of the German Ophthalmological Society (DOG), Retinological Society (RG), Professional Association of Ophthalmologists in Germany e.V. (DVA), German Society of Paediatrics and Adolescent Medicine	1.6	0
121	Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. 2021 , 18, 117-131		1
120	PFKFB3: A Potential Key to Ocular Angiogenesis. 2021 , 9, 628317		2
119	Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2021 , 259, 2849-2855	3.8	0
118	Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity. 2021 , 10, 14		0

117	Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report. 2021 , 25, 180-184	1
116	Anterior segment ischemia after laser for retinopathy of prematurity previously treated with antivascular endothelial growth factor. 2021 , 25, 155.e1-155.e5	
115	Ten-year outcomes after initial management with laser photocoagulation versus intravitreal bevacizumab injection in a pair of identical twins with aggressive posterior retinopathy of prematurity. 2021 , 22, 101097	0
114	CLINICAL FEATURES AND OUTCOMES OF INFANTS WITH RETINOPATHY OF PREMATURE WHO FAIL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. 2021 , 41, 2269-2277	3
113	Complications of retinopathy of prematurity treatment. 2021 , 32, 475-481	1
112	Adult retinopathy of prematurity: treatment implications, long term sequelae, and management. 2021 , 32, 489-493	1
111	Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment. 2021 , 16, 400-407	1
110	Survey of current retinopathy of prematurity practices in China. 2021 , 14, 1241-1247	1
109	The changing face of neonatal intensive care for infants born extremely preterm (. 2021 , 45, 151476	0
108	Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity. 2021 , 66, 877-891	5
107	2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. 2021 , 5, 698-707	7
106	The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity. 2021 , 35, 3302-3310	0
105	Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again. 2021 , 10,	1
104	Retinopathy of Prematurity. 2016 , 21-29	1
103	Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity. 2020 , 24, 149.e1-149.e5	4
102	Bevacizumab for Retinopathy of Prematurity: 2-Year Neurodevelopmental Follow-up. 2021 , 38, 1158-1166	4
101	Retinopathy of prematurity: An update on screening and management. 2016 , 21, 101-8	37
100	Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis. 2020 , 13, 806-815	6

99	Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years. 2015 , 52, 77-84	34
98	Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity. 2016 , 53, 375-382	4
97	Update on the Use of Anti-VEGF Drugs in the Treatment of Retinopathy of Prematurity. 2020 , 57, 351-362	2
96	Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab. 2016 , 47, 280-3	67
95	Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment. 2016 , 47, 1095-1105	10
94	Incomplete Retinal Vascularization After Ranibizumab Treatment of Retinopathy of Prematurity. 2017 , 48, 75-78	8
93	Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab. 2017 , 48, 255-259	53
92	Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP. 2019 , 50, 337-343	20
91	Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP. 2020 , 51, 180-186	1
90	Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database. 2020 , 51, 486-493	2
89	Neonatal Intensive Care Unit-based screening program for retinopathy of prematurity and its treatment in an Indian population. 2019 , 67, 828-833	6
88	Bevacizumab or laser for aggressive posterior retinopathy of prematurity. 2018 , 8, 243-248	10
87	Artificial Intelligence in Retinopathy of Prematurity. 2021 , 127-138	
86	Retinopathy of prematurity: a review of epidemiology and current treatment strategies. 2021 ,	3
85	Current understanding and management of aggressive posterior retinopathy of prematurity. 2015 , 5, 73	
84	Screening and Treatment in Retinopathy of Prematurity. 2015 , 112, 730-5	10
83	Retinopathy of Prematurity. 2016 , 1-38	
82	La r�tinopathie du pr�matur� mise � jour sur le d�bistage et la prise en charge. 2016 , 21, 105-108	1

- 81 Effect of Anti-VEGF Intravitreal Injection on Emmetropization Process. **2016**, 4,
- 80 Blutgasanalyse und Sauerstofftherapie. **2017**, 57-75
- 79 Pharmacomodulation in the Treatment of Retinopathy of Prematurity. **2017**, 79-94
- 78 Retinopathy of Prematurity. **2018**, 2349-2386
- 77 Retinopathy of Prematurity. **2018**, 1-39
- 76 Innovative Approaches in the Delivery of Eye Care: Children. **2019**, 87-106 1
- 75 Commentary: Continuation of care - Refraction beyond regression. **2019**, 67, 877-878
- 74 Commentary: Functional outcome after successful laser for retinopathy of prematurity - Where we stand?. **2019**, 67, 876-877
- 73 Combined Laser and Anti-VEGF Treatment for Zone I ROP. **2019**, 145-147
- 72 Commentary: Antivascular endothelial growth factor and retinopathy of prematurity. **2019**, 67, 969-970 0
- 71 Refractive Status in Children with Laser-Treated Retinopathy of Prematurity: Our Experience in Bulgaria. **2019**, 7, 1320-1323
- 70 Analysis of the clinical characteristics and refraction state in premature infants: a 10-year retrospective analysis. **2019**, 12, 621-626 2
- 69 Retinopathy of prematurity associated with oculocutaneous albinism: Laser treatment is not an option. **2019**, 42, e333-e334
- 68 . **2020**, 237, 1129-1139
- 67 Visual Impairment in Infants and Young Children. **2020**, 1-24
- 66 Therapie der Frühgeborenenretinopathie. **2020**, 09, 293-306
- 65 The restless retina in aggressive posterior retinopathy of prematurity: prevention is better than cure. *Community Eye Health Journal*, **2018**, 31, S27-S28 0.4 1
- 64 Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity. **2021** , 2

63	Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2021 , 1	3.8	○
62	Inter-eye comparison of retinal vascular growth rate and angiographic findings following unilateral bevacizumab treatment. 2021 , 11206721211064019		○
61	Case Report: Glaucoma in an Infant With Retinopathy of Prematurity.. 2021 , 9, 786327		
60	Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.. <i>International Ophthalmology</i> , 2022 , 1	2.2	1
59	Transscleral vs transpupillary diode laser photocoagulation for the treatment of zone II type 1 retinopathy of prematurity: Anatomical and refractive outcomes.. 2022 , 70, 189-193		
58	Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence.. <i>International Ophthalmology</i> , 2022 , 1	2.2	
57	The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.. 2022 ,		○
56	New trends in intravitreal anti-VEGF therapy for ROP.. 2022 , 11206721211073405		○
55	Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.. 2022 , 1		
54	Effect of laser photocoagulation, antiangiogenic therapy or a combined treatment on refractive outcomes of newborns with ROP.. 2022 , 11206721221078668		○
53	Frügeborenenretinopathie. 2022 , 12, 13-32		
52	[Retinopathy of Prematurity - Update on Classification, Screening, and Therapy].. 2022 , 239,		
51	Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.. <i>JAMA Ophthalmology</i> , 2022 , 140, 337-344	3.9	1
50	Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated with Intravitreal Bevacizumab or Laser Photocoagulation.. 2022 ,		○
49	Modeling absolute zone size in retinopathy of prematurity in relation to axial length.. 2022 , 12, 4717		
48	Long-term visual outcomes of children screened for retinopathy of prematurity with telemedicine in New Zealand.. 2022 , 1-6		
47	PARADIGM SHIFT IN MANAGEMENT OF ROP: FROM LASERS TO ANTI-VEGF THERAPY. 2021 , 57-60		
46	Aflibercept for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.. 2021 , 52, 673-681		○

45	Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain. 2021 , 16, e0261095		0
44	Visual Impairment in Infants and Young Children. 2022 , 6691-6714		
43	Risk factors for early-onset high myopia after treatment for retinopathy of prematurity.. 2022 , 1		0
42	National guideline for ophthalmological screening of premature infants in Germany (S2k level, AWMF guidelines register no. 024/010, March 2020) : Joint recommendation of the German Ophthalmological Society (DOG), German Retina Society (RG), Professional Association of Ophthalmologists (BVA), German Society of Ophthalmology (DGO) and German Society of Ophthalmology (DGO) : Joint recommendation of the German Ophthalmological Society (DOG), German Retina Society (RG), Professional Association of Ophthalmologists (BVA), German Society of Ophthalmology (DGO) and German Society of Ophthalmology (DGO)	1.6	1
41	Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection.. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2022 ,	3.8	1
40	Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022 , 9,	4.9	
39	OUTCOME OF THE MANAGEMENT OF AGGRESSIVE RETINOPATHY OF PREMATURETY (A-ROP). 2022 , 11-13		
38	Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.. <i>International Ophthalmology</i> , 2022 ,	2.2	0
37	The restless retina in aggressive posterior retinopathy of prematurity: prevention is better than cure.. <i>Community Eye Health Journal</i> , 2017 , 30, S27-S28	0.4	
36	Comparative Analysis of Intravitreal Ranibizumab versus Laser Therapy for Retinopathy of Prematurity. <i>Archives of Pharmacy Practice</i> , 2022 , 13, 30-36	0	
35	Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. <i>Ophthalmology</i> , 2022 ,	7.3	0
34	Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> ,	3.8	
33	Swept-Source Optical Coherence Tomography in Preschool Children with a History of Treated or Spontaneously Regressed Retinopathy of Prematurity. <i>Seminars in Ophthalmology</i> , 1-6	2.4	0
32	New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics. 2022 , 23, 8529		2
31	Long-term Effects of Anti-VEGF Monotherapy for Retinopathy of Prematurity on the Retinal and Refractive Development of Eye. 2022 , Publish Ahead of Print,		
30	Six years follow-up of Type 1 Retinopathy of Prematurity (ROP) Treated with Intravitreal Injection of Ranibizumab and Bevacizumab.		
29	Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience. 2022 ,		
28	Postnatal Growth Trajectories and Neurodevelopmental Outcomes Following Bevacizumab Treatment for Retinopathy of Prematurity. Volume 16, 2713-2722		

27	Refractive outcomes following unilateral laser treatment for type 1 retinopathy of prematurity. 2022,	0
26	Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab. 2022, 70, 3584	0
25	Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?.	0
24	Advances in the Management of Retinopathy of Prematurity. 2022, 69-85	0
23	Anti-VEGF for Retinopathy of Prematurity. 2022, 15-22	0
22	Quantitative vascular outgrowth and anatomic and refractive outcomes of eyes treated with bevacizumab in posterior zone I. 112067212211328	0
21	Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity. 2022,	0
20	Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.	0
19	Noncoding RNAs as a novel approach to target retinopathy of prematurity. 13,	2
18	Pulmonary function in school-age children following intravitreal injection of bevacizumab for retinopathy of prematurity. 2022, 12,	0
17	Neurodevelopmental Outcomes for Retinopathy of Prematurity: A Nationwide Database Study. 2022,	0
16	Outcomes of near confluent laser versus combined less dense laser and bevacizumab treatment of prethreshold ROP Type 1 Zone 2: a randomized controlled trial. 2022, 22,	0
15	Retinopathy of prematurity.	3
14	Screening, Diagnosis, and Treatment of Pediatric Ocular Diseases. 2022, 9, 1939	2
13	One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.	0
12	Association between myopia progression and quantity of laser treatment for retinopathy of prematurity. 2022, 17, e0279898	0
11	Computed Analysis of Retinal Vascular Growth After Bevacizumab Treatment of Retinopathy of Prematurity Until Age 3 Years. 2022,	0
10	Ophthalmological outcome of 6.5 years children treated for retinopathy of prematurity: a Swedish register study. bjo-2022-322022	0

- 9 Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity. 10, ○
- 8 Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity. **2023**, ○
- 7 Retinopathy of Prematurity in the 21st Century and the Complex Impact of Supplemental Oxygen. **2023**, 12, 1228 ○
- 6 Reactivation of retinopathy of prematurity after intravitreal bevacizumab monotherapy in aggressive posterior retinopathy of prematurity. **2023**, 11, 15 ○
- 5 Current treatment of retinopathy of prematurity. **2017**, 456-461.e2 ○
- 4 Revascularization of immature retinas with retinopathy of prematurity using combination therapy of deferred laser treatment after a single intravitreal bevacizumab injection. **2023**, 38, 28-35 ○
- 3 Eyesight to the Blind Pharmacotherapy for Retinopathy of Prematurity. **2023**, 42, 88-95 ○
- 2 Investigating the factors affecting myopia in retinopathy of prematurity after laser treatment. **2023**, 9, ○
- 1 Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: a multicentre study from J-CREST group. ○